According to Zhitong Finance App, Shiyao Group (01093.HK) announced that a randomized, multi-center, open-label phase III clinical trial evaluating SYS 6043 (B7-H3-ADC) developed by the group compared chemotherapists selected by researchers to treat advanced platinum-resistant ovarian cancer, primary peritoneal cancer, and fallopian tube cancer participants has officially launched at the first center in China.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.